345 related articles for article (PubMed ID: 34771441)
1. The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries.
Deligiorgi MV; Sagredou S; Vakkas L; Trafalis DT
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771441
[TBL] [Abstract][Full Text] [Related]
2. A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors.
Deligiorgi MV; Trafalis DT
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108792
[TBL] [Abstract][Full Text] [Related]
3. Hypophysitis related to immune checkpoint inhibitors: An intriguing adverse event with many faces.
Deligiorgi MV; Liapi C; Trafalis DT
Expert Opin Biol Ther; 2021 Aug; 21(8):1097-1120. PubMed ID: 33393372
[TBL] [Abstract][Full Text] [Related]
4. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer.
Muir CA; Menzies AM; Clifton-Bligh R; Tsang VHM
Thyroid; 2020 Oct; 30(10):1458-1469. PubMed ID: 32264785
[No Abstract] [Full Text] [Related]
6. Hypothyroidism After Use of Immune Checkpoint Inhibitor Therapy in Patient With Graves' Disease: Cure?
Sharma R
JCEM Case Rep; 2023 Jan; 1(1):luac024. PubMed ID: 37908246
[TBL] [Abstract][Full Text] [Related]
7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor-related thyroid dysfunction.
Iwama S; Kobayashi T; Yasuda Y; Arima H
Best Pract Res Clin Endocrinol Metab; 2022 May; 36(3):101660. PubMed ID: 35501263
[TBL] [Abstract][Full Text] [Related]
9. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
10. Combining immune checkpoint inhibitors with denosumab: a new era in repurposing denosumab in oncology?
V Deligiorgi M; Panayiotidis MI; Trafalis DT
J BUON; 2020; 25(1):1-14. PubMed ID: 32277609
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
12. Thyroid-related adverse events induced by immune checkpoint inhibitors.
Chera A; Stancu AL; Bucur O
Front Endocrinol (Lausanne); 2022; 13():1010279. PubMed ID: 36204105
[TBL] [Abstract][Full Text] [Related]
13. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
14. Graves' Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review).
Peiffert M; Cugnet-Anceau C; Dalle S; Chikh K; Assaad S; Disse E; Raverot G; Borson-Chazot F; Abeillon-du Payrat J
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920721
[TBL] [Abstract][Full Text] [Related]
15. Thyroid disorders associated with immune control point inhibitors.
Fidilio E; Navarro-González E; Romero-Lluch AR; Iglesias P; Diez Gómez JJ; Anda Apiñániz E; Santos Mazo E; Zafón C
Endocrinol Diabetes Nutr (Engl Ed); 2021; 68(6):408-415. PubMed ID: 34742474
[TBL] [Abstract][Full Text] [Related]
16. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non-thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists.
Deligiorgi MV; Trafalis DT
Expert Rev Clin Pharmacol; 2022 May; 15(5):531-549. PubMed ID: 35757870
[TBL] [Abstract][Full Text] [Related]
17. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
Salama AK; Moschos SJ
Ann Oncol; 2017 Jan; 28(1):57-74. PubMed ID: 28177433
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
19. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis.
Fitzsimmons TS; Singh N; Walker TDJ; Newton C; Evans DGR; Crosbie EJ; Ryan NAJ
Front Med (Lausanne); 2023; 10():1192762. PubMed ID: 37250628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
